The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for adults with chronic obstructive pulmonary disease (COPD) who continue to struggle ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

These drugs inhibit interleukin (IL)-5, while Dupixent inhibits IL-4 and IL-13, but can be considered a rival because it is also an injection. Patients may opt to take the others because of their ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Dupixent (dupilumab ... The IL-4 and IL-13 targeting antibody is administered as a subcutaneous injection every other week after an initial loading dose, and can be used with or without topical ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising ... formulation requiring less frequent injections. Following FDA approval in August ...